Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp

Journal of the American Academy of Dermatology
Gil TauberEmmilia Hodak

Abstract

Vismodegib has been approved for treatment of locally advanced or metastatic basal cell carcinoma (BCC). Its use for postirradiation multiple BCCs has not yet been reported. We sought to investigate the effectiveness and safety of vismodegib for the treatment of recurrent radiation-induced multiple BCCs. Patients with recurrent multiple BCCs treated with vismodegib and a history of exposure to radiation treatment were followed up prospectively at a tertiary dermato-oncology clinic during a 19-month period. Eight patients met the study criteria. Mean duration of vismodegib treatment was 29 weeks (range 2-52), and of follow-up, 34 weeks (range 8-64). Drug tolerability was acceptable in 7 patients, of whom 4 showed a partial response and 3 had stable disease. In 1 patient, vismodegib was discontinued soon after its initiation because of a severe drug-induced eruption. Small sample size and short follow-up time are limitations. Vismodegib holds promise for the treatment of the subpopulation of patients with radiation-induced multiple BCCs in whom therapeutic options have so far been limited.

References

Oct 12, 2012·Aesthetic Plastic Surgery·Ariel TessoneEyal Winkler
Jul 2, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·C SaintesB Dréno

❮ Previous
Next ❯

Citations

Mar 2, 2016·Radiation Research·Changzhao Li, Mohammad Athar
Jan 20, 2019·Dermatologic Therapy·António CastanheiraPaula Boaventura
Nov 1, 2018·The Australasian Journal of Dermatology·Lauren AndersonChristopher J McCormack

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Basal Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.

© 2021 Meta ULC. All rights reserved